Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Cancer - Breast Cancer
Title   MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Summary   The aim of this study is to create a large-scale, population-based database of genomic information and clinical data to investigate new gene associations. This FLEX Registry is designed to contribute to a better understanding of the relationships between tumor biology, breast cancer treatment and risk of distant recurrence.
Description   MammaPrint and BluePrint identify gene expression within the breast cancer tumor. This FLEX registry will be used to explore relationships between genetic information and the treatment of breast cancer. The FLEX Registry will provide information to help develop additional studies designed to increase knowledge and to improve the treatment of breast cancer.
IRB Number   20172727
Inclusion/Notes   To be eligible for this study, patients must meet several criteria, including but not limited to the following: patients must be 18 years of age or older, be diagnosed with Stage I, II or III invasive breast cancer, and agree to MammaPrint and BluePrint testing.
Status   Active
Start Date   02/15/2017
Principal Name   Nina D’Abreo, MD
Contact Name   Johanna Lee, RN
Email   Johanna.Lee@nyulangone.org
Fax   516-663-1871
Current Trial Type   Registry
Phone   516-663-1237
Alternate Phone   516-663-3115